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ABSTRACT 
 
 
The differences in metabolites in PBMC and in the plasma of patients 
with prediabetes or T2D compared to healthy controls 
 
Ji Yun Han 
Department of Science for Aging 
The Graduate school 
Yonsei University 
 
 
To determine differences between peripheral blood mononuclear cells (PBMC) 
and the plasma matabolomes in patients with prediabetes or type 2 diabetes and 
healthy controls. 65 nononobese patients with prediabetes or newly-diagnosed type 
2 diabetes and 65 nonobese sex-matched healthy controls were enrolled from an 
institutional health screen. After adjusting for age, BMI, blood pressure, and serum 
lipid profiles, the diabetic patients showed higher blood circulation and PBMC 
lipoprotein phospholipase A2 (Lp-PLA2) activities, C-reactive protein (hs-CRP), 
and TNF-α than controls. Compared with controls, diabetic subjects showed 
increases in 11 PBMC metabolites: six amino acids, L-pyroglutamic acid, two fatty 
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acid amides containing palmitic amide, oleamide, and two lysoPCs. In diabetic 
patients, PBMC Lp-PLA2 significantly and positively associated with PBMC 
lysoPCs and inflammatory markers, including TNF-α, hs-CRP, and Lp-PLA2 
activities. When we compared the plasma metabolome of the patients and healthy 
controls, we observed significant increases in only two amino acids and decreases 
in only five lysoPCs. This study demonstrates significant differences in the PBMC 
metabolome in patients with prediabetes or diabetes compared with healthy 
controls. These differences were greater than those observed in the plasma 
metabolome. These data suggest PBMCs as a useful tool to better understand the 
inflammatory pathophysiology of diabetes. 
 
 
 
 
 
 
 
 
 
 
 
                                                                           
Keywords : type 2 diabetes, prediabetes, PBMC metabolites, plasma metabolites, 
 inflammatory markers, Lp-PLA2 , TNF-α, lysoPCs, hs-CR
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1. Introduction 
A number of studies have reported on the metabolic patterns in prediabetic or 
diabetic patients (1-6). In a nested case-control study design, the Framingham 
Offspring study found that three branched chain amino acids (isoleucine, leucine, 
and valine) and two aromatic amino acids (tyrosine and phenylalanine) could 
predict the future development of diabetes in otherwise healthy individuals (1). Xu 
et al. recently reported that impaired fasting glucose (IFG) and type 2 diabetes 
(T2D) are characterized by abnormalities in amino acids, fatty acids, 
glycerophospholipids, and sphinglomyelin metabolism (2). In addition, Menni et al. 
found a novel association between the branched-chain keto acid metabolite, 3-
methyl-2-oxovalerate, and IFG in both plasma and urine (3). 
In early onset T2D, peripheral blood mononuclear cells (PBMC) are sensitive to 
a variety of stimuli; thus, individuals with T2D show a greater inflammatory 
reaction of PBMC than those without diabetes (7). PBMC consist of monocytes 
and lymphocytes. Blood monocytes play a key role in the onset and development 
of the inflammatory reaction by generating bioactive molecules, such as 
proinflammatory cytokines and lipoprotein phospholipase A2 (Lp-PLA2) (7, 8). 
Inflammatory processes have been increasingly recognized as a critical step in the 
pathogenesis of diabetes (9). Therefore, measuring the PBMC metabolome could 
provide a novel source of IFG/T2D biomarkers (10). The aim of this study was to 
assess the differences in metabolites in PBMC and in the plasma of patients with 
prediabetes or T2D compared to healthy controls. 
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2. Background 
2.1. Diabetes 
2.1.1. Type 2 diabetes 
T2D is one of the most common chronic worldwide diseases; as a result 
prevalence of T2D is increasing at epidemic proportions. Population growth, 
dramatic increase in average life expectancy, and urbanization with associated 
changed life style are likely to lead to a 54% increase in worldwide numbers with 
diabetes by 2030 (11). This increase in T2D prevalence is also associated with 
increase in both morbidity and mortality (12). Mortality rate from diabetes has 
increased rapidly from 7.4% in 1988 to 25% in 2003 and has remained at 
approximately 20% since that time (13). Furthermore diabetic complications such 
as neuropathy, retinopathy, nephropathy and coronary diseases have a substantial 
and direct impact on medical costs (14). 
 T2D formerly called non insulin dependent diabetes mellitus, It is characterized 
by defects in both insulin secretion and insulin action (15). The risk of developing 
T2D increases with age, obesity, physical inactivity (16). Recent clinical trials have 
demonstrated that, changes in lifestyle and pharmacological intervention both 
reduces the incidence of diabetes with persons at high risk. Surprisingly, the 
lifestyle intervention shows more effective result than pharmacological treatment 
(17). 
 Below are 4 criteria for the diagnosis of diabetes according to the American 
Diabetes Association (ADA) (16). 
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1. glycated haemoglobin A1C (HbA1C) ≥ 6.5% 
2. fasting plasma glucose (FPG) ≥ 126mg/dl  
(Fasting is defined as no caloric intake for at least 8h) 
3. 2-h plasma glucose ≥ 200mg/dl during on oral glucose tolerance test (OGGT) 
4. A patients with classic symptoms of hyperglycemia or hyperglycemic crisis 
with a random plasma glucose ≥ 200mg/dl 
 
2.1.2. prediabetes 
Subjects with prediabetes have high risk for the future development of diabetes. 
5~10% of people per year with prediabets will progress to diabetes (18). 
According to the ADA, people are at risk of developing diabetes if they have one 
of two distinct states: One is a IFG, defined as a FPG concentration 100 to 
125mg/dl, without impaired glucose tolerance (IGT), and second is a IGT 
concentration 140 to 199mg/dl, measured during a 75g OGGT. And HbA1C 5.7-6.4% 
as a category for high diabetes risk (16). 
Prediabetes should be treated to prevent progression to diabetes. Most studies 
have focused on diabetes incidence in prediabetic individuals, and support opinion 
that change in lifestyle should be the first option for diabetes prevention (18). 
The primary aim of lifestyle interventions is to prevent or delay development of 
T2D and its complication (19) by targeting obesity and physical inactivity, which 
are the two most important modifiable risk factor of diabetes development (20). 
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2.2. Metabolites 
Metabolomics is defined as the quantitative measurement of the time-related 
multiparametric metabolomic response of living systems to pathophysiological 
stimuli or genetic modification. Based on the multivariate analysis of complex 
biological profiles, metabolomics has recently demonstrated enormous potential in 
many fields, such as disease diagnosis and toxicological mechanism and drug 
effects (21). Metabolites are small molecules that participate in metabolic reactions 
and have an important role in biological systems (22). Metabolomics studies can be 
performed using blood (serum, plasma), urine, cerebrospinal fluid, lymph fluid, 
bile, feces, saliva, cells, tissues and tissue or cell metabolic foot prints (22). Several 
studies have championed the potential use of PBMC, a group of cells, including 
lymphocytes and monocytes/macrophages, in characterizing gene expression 
patterns distinctive for certain disease (23). 
Metabolic profiling of PBMC could serve as a less invasive and more direct 
alternative to tissue biopsies or serum in metabolomic research. The utility of 
metabolomic profiling of PBMCs and paves the way for future applications of 
metabolomics in identifying metabolic profiles of blood cells as a measure for 
dietary intake of physiological status (24). 
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2.3. Inflammtory markers & Type 2 diabetes 
2.3.1. Lipoprotein-associated phospholipase A2 
Lipoprotein-associated phospholipase A2 (Lp-PLA2) is a member of the 
phospholipase A2 superfamily, a family of enzymes that hydrolyze phospholipids. 
Lp-PLA2 is a proinflammatory enzyme secreted by macrophages that is primarily 
bound to low density lipoprotein (LDL) in the circulation. It hydrolyzes oxidized 
phospholipids to generate lysophosphatidylcholine and oxidixed fatty acid, which 
have proinflammatory properties, and its activity is increased in small dense LDL 
(25). 
 Levels of Lp-PLA2 activity were significantly associated with incident coronary 
heart disease (CHD) among men and women with T2D, independent of traditional 
and inflammatory risk factors (26). 
 
2.3.2. Tumor necrosis factor-α 
Tumor necrosis factor-α (TNF-α), a paracrine/autocrine factor highly expressed in 
adipose tissues of obese animals and human subjects, is implicated in the induction 
of insulin resistance seen in obesity and T2D (27). Other studies have demonstrated 
synthesis of TNF-α in muscle and adipose tissue also have implicated TNF-α in the 
pathogenesis of insulin resistance (IR) (28). Concentrations of acute-phase 
response markers and mediators of inflammation – cytokines such as TNF-α and 
interleukin-6 (IL-6) are raised in people with T2D. An association between high 
plasma levels of TNF-α and several metabolic abnormalities characteristic for the 
insulin resistance syndrome suggests that TNF-α may be involved in the 
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pathogenesis of T2D(29). 
 
2.3.3. Lysophophatidyl choline 
Lysophophatidyl choline (Lyso-PC) plays a critical role in atherogenesis. It acts a 
chemoatractant for monocytes, impairs endothelial function, cause cell death by 
disrupting plasma membranes, and induces apoptosis in smooth muscle cells and 
macrophages (30,31). Others have reported increased lyso-PC content in LDL in 
patients with diabetes mellitus compared with non diabetic control (32). The lyso-
PC content in LDL correlated with serum LP-PLA2 level, and increased lyso-PC in 
LDL was associated with microangiopathy in diabetic patients (33). 
 
2.3.4. C-reactive protein 
C-reactive protein (CRP) is an acute-phase reactant that is part of the immune 
response to injury and infection (34). CRP is a marker of low-grade inflammation 
and may have indirect influence on insulin resistance and insulin secretion through 
altered innate immune response due to heightened systemic inflammation (35). 
Elevated CRP levels are a strong independent predictor of T2D (36). The 
magnitude of association between CRP and diabetes appears to be comparable or 
even stronger than the association of CRP with coronary heart disease observed in 
previous studies (37). 
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3. Materials and Methods 
3.1 Subjects and Study Design 
Study subjects were selected from participants in a clinical nutrition study 
conducted by the National Leading Research Laboratory of Clinical 
Nutrigenetics/Nutrigenomics at Yonsei University. Nonobese subjects  (18.5 ≤ 
BMI < 30 kg/m
2
), 30-70 years old, were recruited from the Health Service Center 
(HSC) during routine check-ups at the National Health Insurance Corporation Ilsan 
Hospital, Goyang, Korea (January 2013–June 2013). Based on the data screened 
from HSC, subjects who were in IFG (100 ≤ fasting glucose < 126 mg/dL) or 
newly diagnosed T2D (fasting glucose ≥ 126 mg/dL) were referred to the 
Department of Family Medicine or Internal Medicine. Subjects were excluded if 
they took: lipid-lowering medications, any medications or supplements known to 
affect lipid metabolism, or any probiotics products in the past month. Subjects were 
excluded if they were diagnosed with dyslipidemia, diabetes mellitus, hypertension, 
liver disease, renal disease, cardiovascular disease, cerebrovascular disease, 
pancreatitis, or cancer; history of medication or alcohol abuse; or were pregnant or 
breast feeding. A total of 65 nonobese subjects with prediabetes or newly 
diagnosed T2D (age 30-70 years) were enrolled, and 65 nonobese sex-matched 
healthy subjects were enrolled for the control group. The macronutrient 
composition of each subject’s usual diet was that of a typical diet, which is 
consumed by a substantial number of Koreans. This diet derives about 63% of its 
energy from carbohydrates, 21% from fat, and 16% from protein. All subjects 
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provided written informed consent before participation in this study, which was 
approved by the Institutional Review Board of Yonsei University and Ilsan 
Hospital. 
 
3.2 Anthropometric parameters, blood pressure, and blood collection 
Weight and height were measured without clothes and shoes, and BMI was 
calculated by kilograms per square meter (kg/m
2
). Waist and hip circumferences 
were measured using a plastic measuring tape and used to calculate the waist to hip 
ratio (WHR). After a 20-minute rest, blood pressure (BP) was measured two times 
in the left arm of seated subjects with an automatic BP monitor (FT-200S, Jawon 
Medical, Gyeongsan, Korea). After a 12-hour fasting period, venous blood 
specimens were collected in EDTA-treated whole blood and serum tubes. The 
blood samples were centrifuged to obtain plasma and serum. The collected samples 
were stored at -70°C. 
 
3.3 Fasting glucose, insulin, homeostasis-model assessment of insulin 
resistance, and hemoglobin A1c 
Fasting glucose levels were analyzed by the hexokinase method using a Hitachi 
7600 Autoanalyzer. Insulin levels were measured by an immunoradiometric assay 
kit from DIAsource ImmunoAssays S.A. (Louvain, Belgium). IR was calculated by 
the homeostasis-model assessment (HOMA) using the following equation: HOMA-
IR = [Fasting insulin (μIU/mL) × Fasting glucose (mmol/L)] / 22.5. Hemoglobin 
A1c (HbA1c) was measured by immonoturbidimetric analysis. 
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3.4 Serum lipid profile and free fatty acids 
Fasting triglyceride and total cholesterol were measured using a Hitachi 7600 
Autoanalyzer (Hitachi Ltd., Tokyo, Japan). HDL-cholesterol left in the supernatant 
fraction was measured by an enzymatic method after other lipoprotein precipitation. 
LDL-cholesterol was indirectly calculated using the Friedwald formula; LDL 
cholesterol = total cholesterol – [HDL cholesterol + (triglyceride/5)] for subjects 
with a serum triglyceride level < 400 mg/dL. LDL-cholesterol was measured 
directly using a Hitachi 7600 Autoanalyzer for subjects with a serum triglyceride 
level ≥ 400 mg/dL. Free fatty acids (FFA) were measured by enzymatic assay with 
the acylCoA synthetase-acylCoA oxidase (ACS-ACOD) method using a Hitachi 
7600 Autoanalyzer. 
 
3.5 Measurement of serum high-sensitivity C-reactive protein, Lp-PLA2 
activity, plasma malondialdehyde, LDL particle size, and oxidized LDL 
Serum high-sensitivity C-reactive protein (hs-CRP) was measured with an 
ADVIA 2400 Clinical Chemistry System (Siemens Ltd., Tarrytown, NY) using a 
commercially available, high-sensitivity CRP-Latex(II) X2 kit (Denka-Seiken Co., 
Ltd., Tokyo, Japan). Lp-PLA2 activity was measured using a modified high-
throughput radiometric activity assay (38). Plasma malondialdehyde (MDA) was 
measured from thiobarbituric acid-reactive substances (TBARS) using a TBARS 
Assay Kit (ZeptoMetrix Co., Buffalo, NY). LDL particles were isolated by 
sequential flotation ultracentrifugation. Particle size distribution (1.019–1.063 
g/mL) was examined using a pore-gradient lipoprotein system (CBS Scientific 
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Company, San Diego, CA) using commercially available, non-denaturing gels 
containing a linear 2-16% acrylamide gradient (CBS Scientific Company). Latex-
bead (30 nm) conjugated thyroglobulin (17 nm), ferritin (12.2 nm), and catalase 
(10.4 nm) standards were used to estimate the relative band migration rates. Gels 
were scanned using a GS-800 Calibrated Imaging Densitometer (Bio-Rad 
Laboratories, Hercules, CA). Plasma oxidized (ox)-LDL was measured using an 
enzyme immunoassay (Mercodia AB, Uppsala, Sweden), and the resulting color 
reaction was determined at 450 nm on a Wallac Victor2 multilabel counter (Perkin-
Elmer Life Sciences, Boston, MA).  
 
3.6 Urinary 8-epi-prostaglandin F2α and TNF-α measurements 
Urine was collected in polyethylene bottles containing 1% butylated 
hydroxytoluene after a 12-h fast, and bottles were immediately covered with 
aluminum foil and stored at −20°C until further analysis. Levels of 8-epi-
prostaglandin F2α (8-epi-PGF2α) were measured using a Urinary Isoprostane ELISA 
kit (Oxford Biomedical Research Inc., Rochester Hills, MI). Urinary creatinine 
levels were determined by the Creatinine Jaffe Method. Serum TNF-α 
concentrations were measured using the Bio-Plex Reagent Kit and a Bio-Plex (Bio-
Rad Laboratories, Inc.) according to manufacturer instructions. 
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3.7 Global (nontargeted) metabolic profiling of plasma 
Sample preparation and analysis 
Prior to analysis, 800 µL of 80% acetonitrile was added to 100 µL of plasma, 
mixed by vortexing, and centrifuged at 10,000 rpm for 5 min at 4°C. The 
supernatant was dried with N2 (l), dissolved in 10% methanol, mixed by vortexing, 
and centrifuged at 10,000 rpm for 5 min at 4°C. The supernatant was transferred 
into a vial. 
Ultra performance liquid chromatography 
Plasma extract samples (4 µL) were injected into an Acquity UPLC-BEH-C18 
column (2.1 × 50 mm, 1.7 μm; Waters, Milford, MA), which was coupled in-line 
with a UPLC-LTQ-Orbitrap XL (Thermo Fisher Scientific, USA). The injected 
samples were equilibrated with water containing 0.1% formic acid. Samples were 
eluted with an acetonitrile gradient containing 0.1% formic acid at a flow rate of 
0.35 mL/min for 20 min. Metabolites were separated by UPLC (Thermo Fisher 
Scientific, USA), analyzed, and assigned by LTQ-Orbitrap-XL (Thermo Fisher 
Scientific, USA). The mass spectrometer was operated in the ESI-positive mode. 
The spray voltage was 5 kV. The flow rate nitrogen sheath gas and the auxiliary gas 
were 50 and 5 (arbitrary units). The capillary voltage (V), tube-lens voltage (V), 
and capillary temperature (°C) were kept constant at 35 V, 80 V, and 370°C. The 
Orbitrap data were collected in the range of m/z 501,000. The MS/MS spectra of 
metabolites were obtained by a collision-energy ramp from 5565 eV, and 
conducted with Xcalibur 2.1 and MS Frontier software (Thermo Fisher Scientific, 
USA). 
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Data processing and identification of metabolites 
All MS data including retention times, m/z, and ion intensities were extracted by 
SIEVE software (Thermo Fisher Scientific, USA) incorporated into the instrument, 
and the resulting MS data were assembled into a matrix. SIEVE parameters were 
set as follows: m/z range 501,000; m/z width 0.02; retention time width 2.5; and 
m/z tolerance 0.005. Metabolites were searched using the following databases: 
ChemSpider (www.chemspider.com), Human Metabolome (www.hmdb.ca), Lipid 
MAPS (www.lipidmaps.org), KEGG (www.genome.jp/kegg), and MassBank 
(www.massbank.jp). Selected metabolites were confirmed by standard samples 
based on both retention times and mass spectra. 
 
3.8 Statistical analyses 
Statistical analyses were performed using SPSS v. 21.0 software (IBM/SPSS 
Corp. Chicago, IL). Skewed variables were logarithmically transformed for 
statistical analyses. For descriptive purposes, mean values were presented using 
untransformed values. Results were expressed as means ± standard error (SE). A 
two-tailed P-value of < 0.05 was considered statistically significant. Differences in 
biochemical characteristics between two groups were tested using Student’s 
independent t-test. General linear model (GLM) tests were applied to compare 
parameter changes between the two groups by adjusting for baseline values. 
Pearson’s and partial correlation coefficients were used to examine the 
relationships between variables over time. False discovery rate (FDR)-corrected q-
values were computed using the R package ‘fdrtool’. Heat maps were created to 
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visualize and evaluate correlations among metabolites and biochemical 
characteristics in the study populations. 
Multivariate statistical analysis was performed using SIMCA-P+ software 
version 12.0 (Umetrics, Umeå, Sweden). Partial least-squares discriminant analysis 
(PLS-DA) was used as the classification method for modeling the discrimination 
between healthy controls and subjects with IFG or T2D by visualizing the score 
plot or S-plot using the first and second PLS components. To validate the model, a 
seven-fold validation was applied to the PLS-DA model, and the reliabilities of the 
model were further rigorously validated by a permutation test (n = 200). The 
goodness of the fit was quantified by R
2
Y, whereas the predictive ability was 
quantified by Q
2
Y. Generally, R
2
Y describes how well the data in the training set 
are mathematically reproduced, and this varies between 0 and 1 (a value of 1 
indicates a model with a perfect fit). Models with Q
2
Y  0.5 are considered to have 
good predictive capabilities. 
 
 
 
 
 
 
 
 
 
14 
 
4. Results 
4.1 Clinical characteristics and nutrient intake 
Clinical and biochemical characteristics of healthy controls with normal fasting 
serum glucose level and subjects with IFG or newly diagnosed T2D are shown in 
Table 1. There were no significant differences in clinical characteristics, such as 
male/female distribution (25/40 vs. 25/40), education level, smoking, drinking, and 
total calorie and macronutrient intake (data not shown) between control and patient 
groups. The patient group was significantly older and heavier and had higher 
diastolic BP, serum triglyceride, and FFA compared to controls. After adjusting for 
age, BMI, BP, and serum lipid profiles, when compared with control subjects those 
with IFG or T2D showed higher glucose, HbA1C, insulin, HOMA-IR, hs-CRP, 
circulating plasma and PBMC Lp-PLA2 activities, ox-LDL, 8-epi-PGF2α, MDA, 
and TNF-α. The patient group also had a smaller LDL particle size compared with 
controls (Table 1). 
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Table 1. Clinical and biochemical characteristics in each group 
Mean ± SE. 
∮
Tested by logarithmic transformation, P-values derived from independent t-test. P1 
adjusting for age, BMI, WHR, smoking, drinking, BP, triglyceride, total cholesterol, HDL, LDL, 
and FFA
 NFG (n=65) IFG + T2D (n=65) P P1 
Age (year)  48.2 ±1.12   54.0 ±1.00  <0.001 - 
Body mass index (kg/m2)  22.8 ±0.35   24.0 ±0.34  0.014 - 
Waist hip ratio  0.87 ±0.01   0.90 ±0.01  0.008 - 
Systolic BP (mmHg)  118.3 ±1.54   125.8 ±1.61  0.001 - 
Diastolic BP (mmHg)  77.4 ±1.29   80.2 ±1.15  0.111 - 
Triglyceride (mg/dL)
∮
  100.7 ±5.38   126.8 ±7.73  0.013 - 
Total-cholesterol (mg/dL)
∮
  198.5 ±3.35   195.6 ±4.61  0.434 - 
HDL-cholesterol (mg/dL)
∮
  54.4 ±1.84   48.3 ±1.34  0.023 - 
LDL-cholesterol (mg/dL)
∮
  122.8 ±3.17   121.9 ±4.06  0.650 - 
Free fatty acid (μEq/L)
∮
  389.2 ±24.5   488.5 ±23.5  0.001 - 
Glucose (mg/dL)
∮
  88.7 ±1.06   119.9 ±3.59  <0.001 <0.001 
HbA1c (%)
∮
  5.76 ±0.01   6.47 ±0.09  <0.001 <0.001 
Insulin (μIU/dL)
∮
  7.01 ±0.77   7.58 ±0.42  0.032 0.009 
HOMA-IR
∮
  1.54 ±0.17   2.22 ±0.13  <0.001 <0.001 
hs-CRP (mg/dL)
∮
  0.45 ±0.14   1.73 ±0.36  <0.001 <0.001 
LDL particle size (nm)
∮
  23.5 ±0.08   23.0 ±0.11  0.001 0.012 
Lp-PLA2 activity 
(nmol/mL/min)
∮
 
 26.8 ±0.75   31.7 ±0.74  <0.001 <0.001 
PBMC Lp-PLA2 activity 
(nmol/mL/min)
∮
 
 1.47 ±0.05   2.07 ±0.10  <0.001 <0.001 
Oxidized LDL (U/L)
∮
  40.8 ±1.48   53.9 ±1.91  <0.001 <0.001 
8-epi-PGF2α (pg/mg 
creatinine)
∮
 
 1156.1 ±50.6   1833.6 ±81.2  <0.001 <0.001 
Malondialdehyde 
(nmol/mL)
∮
 
 7.88 ±0.28   8.97 ±0.29  0.002 0.010 
Serum TNF-α (pg/mL)
∮
  7.31 ±1.23   12.3 ±1.83  <0.001 0.001 
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4.2 PBMC and plasma metabolic profiling using UPLC-LTQ-Orbitrap mass 
spectrometry 
Nontargeted metabolic pattern analysis 
The mass spectrometry (MS) data of PBMC metabolites were analyzed with a 
PLS-DA score plot (Fig. 1A). The two-component PLS-DA score plot of the 
PBMC metabolites showed distinct clustering and clear separation for each of the 
healthy controls away from those subjects with IFG or T2D. Both groups could be 
clearly differentiated from each other by the primary component t(1) or the 
secondary component t(2) based on the model with R
2
X(cum) and R
2
Y(cum) values 
of 0.256 and 0.682, respectively, indicating a good fit of the data. The Q
2
Y(cum) 
value of 0.608 provides an estimate of the predictive ability of this model. The 
PLS-DA model was validated using a permutation test, which indicated an R
2
Y 
intercept value of 0.258 and a Q
2
Y intercept value of 0.185.  
The MS data of plasma metabolites were analyzed with a PLS-DA score plot 
(Fig. 1B). The two-component PLS-DA score plot of the plasma metabolites 
showed distinct clustering and clear separation for each of the healthy controls 
away from that observed for subjects with IFG or type 2 diabetes. Both groups 
could be clearly differentiated from each other by the primary component t(1) or 
the secondary component t(2) based on the model with R
2
X(cum) and R
2
Y(cum) 
values of 0.12 and 0.708, respectively, indicating a good fit of the data. The 
Q
2
Y(cum) value of 0.414 provides an estimate of the predictive ability of the model. 
The PLS-DA model was validated using a permutation test, which indicated an R
2
Y 
intercept value of 0.486 and a Q
2
Y intercept value of 0.0496. To identify the 
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metabolites that contributed to the differentiation between healthy controls and IFG 
or diabetic subjects, S-plots of p(1) and p(corr)(1) were generated using centroid 
scaling (Fig. 1 C and D). The S-plots revealed that metabolites with higher or lower 
p(corr) values were more relevant for discriminating between the two groups. 
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Figure 1.  
Identification of PBMC and plasma metabolites with significantly altered 
levels in each subgroup. A: Score plots of PBMC metabolites from PLS-DA 
models classifying in NFG (n=65) and IFG or T2D group (n=65). B: Score plots of 
plasma metabolites from PLS-DA models classifying in NFG (n=65) and IFG or 
T2D group (n=65). C&D: S-plots for covariance [p], and the reliability correlation 
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[p(corr)] from PLS-DA models. 
Identification of PBMC metabolites 
Of 1,948 PBMC metabolites, those that correlated with a separation between the 
groups were identified by the variable important in the projection (VIP) parameter. 
VIP values > 1.0 were considered highly relevant for group differences. Thirty-six 
metabolites were selected based on VIP values > 1.0; 11 of these were previously 
identified, and 25 were unknown. Eleven PBMC metabolites (VIP > 1.0) are 
shown in Table 2. The normalized peak intensities of 6 amino acids (valine, leucine, 
methionine, phenylalanine, tyrosine, tryptophan) were significantly higher in 
PBMCs of IFG or diabetic subjects compared to those of control subjects (all q-
values < 0.001). L-pyroglutamic acid, two fatty acid amides containing palmitic 
amide and oleamide, and two lysoPC containing C16:0, C18:0 were significantly 
higher in PBMCs of IFG or diabetic subjects than in those of control subjects 
(Table 2). 
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Table 2. Identification of PBMC metabolites in each group 
 
Mean ± SE
Identity 
Formula 
[M +H]
+
 
Exact 
Mass 
(M+H) 
 Normalized peak intensities 
q-value VIP 
 NFG (n=65)  IFG + T2D (n=65) 
L-Valine C5H11NO2 118.0868  888316 ±37074  1057811 ±30070 4.2☓10
-4
 1.3129 
L-Pyroglutamic acid C5H7NO3 130.0504  1768814 ±108739  2440611 ±84749 4.2☓10
-6
 5.0910 
L-Leucine C6H13NO2 132.1024  5845735 ±146747  7718791 ±205605 <1.0☓10
-9
 14.4867 
L-Methionine C5H11NO2S 150.0589  572911 ±24036  786394 ±26709 5.8☓10
-8
 1.6523 
L-Phenylalanine C9H11NO2 166.0868  2118750 ±74031  2703044 ±64325 4.0☓10
-8
 4.5446 
L-Tyrosine C9H11NO3 182.0817  1197246 ±34486  1508002 ±36979 2.1☓10
-8
 2.4183 
L-Tryptophan C11H12N2O2 205.0977  674782 ±18517  813131 ±20492 2.5☓10
-6
 1.0979 
Palmitic amide C16H33NO 256.2640  189455 ±36005  416239 ±64030 1.6☓10
-3
 1.7109 
Oleamide C18H35NO 282.2797  1813863 ±371626  3295742 ±501718 9.3☓10
-3
 11.1721 
LysoPC (16:0) C24H50NO7P 496.3403  308429 ±43686  487640 ±44173 2.7☓10
-3
 1.3651 
LysoPC (18:0) C26H54NO7P 524.3716  247036 ±33381  399886 ±32969 9.8☓10
-4
 1.1729 
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Identification of plasma metabolites 
Among 4,164 metabolites in the plasma, we identified those that played 
important roles in the separation between the groups by selecting according to the 
Variable Important in the Projection (VIP) parameter. VIP values > 1.0 were 
considered to be highly relevant for the generating the difference between the 
sample groups. Eighty-one plasma metabolites were selected based on VIP values 
> 1.0; 12 of these metabolites and PCs were previously identified, and 69 
metabolites were unknown. Twelve plasma metabolites and PCs are shown in 
Table 3. The normalized peak intensities of two amino acids (proline, valine) were 
significantly higher in the plasma of IFG or diabetic subjects compared to the peak 
intensities observed in control subjects (both q-values <0.001). Five lysoPC 
containing C16:0, C17:0, C18:2, C18:1, and C18:0 were significantly lower in the 
plasma of IFG or diabetic subjects compared with control subjects (Table 3). 
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Table 3. Identification of plasma metabolites in each group 
 
Mean ± SE. 1PCs were not successfully separated by C18-UPLC used in this study, but detected by Orbitrap MS. Thus, the amounts of all detected PCs were 
 combined together. 
Identity 
Formula 
[M +H]+ 
Exact 
Mass 
(M+H) 
 Normalized peak intensities 
q-value VIP 
 NFG (n=65)  IFG + T2D (n=65) 
L-Proline C5H9NO2 116.0712  276492 ±15880  414602 ±18452 8.6☓10
-7 1.1046 
L-Valine C5H11NO2 118.0868  1167581 ±37876  1302131 ±23979 8.8☓10
-3 1.1138 
L-Leucine C6H13NO2 132.1024  2692278 ±113534  3031235 ±65932 0.232 2.7660 
L-Phenylalanine C9H11NO2 166.0868  1799375 ±58017  1939404 ±36325 0.066 1.1481 
Oleamide C18H35NO 282.2797  7273413 ±588229  7897810 ±644605 0.292 13.3814 
LysoPC (16:0) C24H50NO7P 496.3403  18894117 ±658364  16807599 ±459092 0.022 16.9894 
LysoPC (17:0) C25H52NO7P 510.3559  943675 ±63110  744399 ±35337 0.016 1.4135 
LysoPC (18:2) C26H50NO7P 520.3403  6873739 ±259398  6005440 ±176424 0.016 6.0622 
LysoPC (18:1) C26H52NO7P 522.3559  6027713 ±224255  5336388 ±160530 0.027 4.8448 
LysoPC (18:0) C26H54NO7P 524.3716  6830842 ±261237  6019618 ±155138 0.019 5.7595 
LysoPC (20:4) C28H50NO7P 544.3403  2048369 ±86854  2144722 ±91164 0.280 2.5718 
Lactosylceramide 
(d18:1/12:0) 
C42H79NO13 806.5629  5824805 ±467128  6640208 ±481304 0.197 8.2140 
1PCs    37066131 ±1525042  35406576 ±1441222 0.274  
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4.4 Correlations among fasting glucose, plasma and PBMC Lp-PLA2 activities, 
biochemical parameters, and major PBMC and plasma metabolites 
The correlation matrix among fasting glucose, plasma and PBMC Lp-PLA2 
activities, biochemical parameters, and major PBMC and plasma metabolites was 
computed for all subjects (n = 130) as well as for the control and patient groups 
(Fig. 2). In all subjects, fasting glucose, plasma and PBMC Lp-PLA2 activities, 
biochemical parameters, and major PBMC and plasma metabolites were highly 
correlated. For example, fasting glucose correlated positively with HOMA-IR, ox-
LDL, plasma and PBMC Lp-PLA2, hs-CRP, TNF-α, 8-epi-PGF2α, PBMC valine, 
L-pyroglutamic acid, leucine, methionine, phenylalanine, and tyrosine; plasma 
proline, valine, leucine, and phenylalanine. Fasting glucose negatively correlated 
with LDL particle size and plasma lysoPCs containing C17:0 and C18:2. 
In the control group, fasting glucose positively correlated with PBMC valine and 
tryptophan. Plasma Lp-PLA2 activity positively correlated with PBMC Lp-PLA2 (r 
= 0.273, P = 0.032), phenylalanine, tyrosine, and lysoPC 18:0 (r = 0.251, P = 
0.048). PBMC Lp-PLA2 activity correlated positively with HOMA-IR, hs-CRP, 
PBMC leucine, methionine, phenylalanine, tyrosine, palmitic amide, oleamide, 
lysoPC (16:0) (r = 0.273, P = 0.030), lysoPC (18:0) (r = 0.266, P = 0.035); plasma 
valine, leucine, phenylalanine, oleamide, lysoPCs containing C16:0, C17:0, C18:2, 
C18:1, C18:0 and C20:4. Fasting glucose negatively correlated with LDL particle 
size. 
In the patient group, plasma Lp-PLA2 activity strongly and positively correlated 
with ox-LDL (r = 0.464, P < 0.001), 8-epi-PGF2α (r = 0.500, P < 0.001), TNF-α, 
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and PBMC Lp-PLA2 (r = 0.518, P < 0.001). PBMC Lp-PLA2 activity positively 
correlated with hs-CRP, TNF-α, ox-LDL (r = 0.445, P < 0.001), PBMC 
phenylalanine, palmitic amide, oleamide, lysoPC 16:0 (r = 0.421, P < 0.001), and 
lysoPC 18:0 (r = 0.415, P < 0.001) (Fig. 2). 
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Figure 2.  
Correlation matrix among metabolites and biochemical characteristics in each  
group. All biochemical characteristics were tested by logarithmic transformation.  
Correlations were obtained by deriving a Spearman correlation coefficient. PBMC  
metabolites (11), plasma metabolites (13), and biochemical characteristics (9) are  
listed on the right side of the heat map with the nine biochemical characteristics  
listed across the top. Red represents a positive correlation, and purple represents a  
negative correlation. 
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5. Discussion 
The major finding of this study is that, compared with plasma metabolites, the 
PBMC metabolites show unique metabolomic features and have a greater 
difference between patients with prediabetes or T2D compared to healthy controls. 
Accounting for prediabetes- or diabetes-related alterations of PBMC and plasma 
major metabolites, we identified 11 PBMC metabolites to be significantly different 
between control and patient groups. These included six amino acids (valine, leucine, 
methionine, phenylalanine, tyrosine, tryptophan), L-pyroglutamic acid, palmitic 
amide, oleamide, and two lysoPCs containing C16:0, C18:0. Comparatively, there 
were significant differences in seven plasma metabolites, including two amino 
acids (proline and valine) and five lysoPCs containing C16:0, C17:0, C18:2, C18:1, 
C18:0. In patients with prediabetes or T2D, the positive associations among PBMC 
Lp-PLA2, PBMC lysoPCs, and circulating inflammatory markers (TNF-α, hs-CRP, 
Lp-PLA2 activity) agrees with previous data indicating that PBMCs have a greater 
inflammatory reaction in individuals with T2D compared with those without T2D 
(7). Therefore, these results support the recent proposal that due to their active 
metabolism, PBMC may be useful to better understand the pathophysiology of 
chronic diseases (10, 39). Furthermore, these results indicate that subset of PBMC 
metabolites are unique from plasma metabolites, suggesting a possible enhanced 
effectiveness of using this approach compared to plasma metabolomics alone. 
In a nested case-control study design, five plasma branched-chain and aromatic 
amino acids (isoleucine, leucine, valine, tyrosine and phenylalanine) had 
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significant associations with the development of diabetes (1). Our cross-sectional 
investigation also showed PBMC branched-chain and aromatic amino acids and 
methionine to be significantly elevated in subjects with IFG or T2D. Unlike PBMC 
metabolites, only two plasma amino acids, proline and valine, showed significant 
differences when comparing the control and patient groups. This discrepant finding 
may indicate divergent mechanisms used by different tissues to control metabolites. 
Pyroglutamic acid is important in the intracellular transport of free amino acids, 
and Xu et al. found serum pyroglutamic acid to be lower in patients with diabetes 
(2). In contrast, in the current study PBMC pyroglutamic acid was higher in 
subjects with IFG or T2D. Furthermore, we observed discrepancies between 
lysoPCs in plasma compared with that of PBMC. We detected lower lysoPCs in the 
plasma and higher lysoPCs in PBMC in subjects with IFG or T2D compared 
controls. 
Compared with healthy patients, those patients with IFG or T2D showed an 
increase in plasma ox-LDL as well as elevations in PBMC Lp-PLA2 activities and 
PBMC lysoPCs. The observed strong association between PBMC Lp-PLA2 and ox-
LDL supports previously published data demonstrating a direct effect of ox-LDL 
on the expression of Lp-PLA2 in THP-1 monocytes (40). Indeed, plasma ox-LDL 
has been suggested to have a causal role in upregulating Lp-PLA2 mRNA 
expression in PBMC of smokers (41). Lp-PLA2 hydrolyzes oxidized phospholipids 
in LDL particles at the sn-2 position and produces bioactive oxidized free fatty 
acids and lysoPCs. In the present study, strong positive associations among plasma 
ox-LDL, PBMC Lp-PLA2 activities, PBMC lysoPC (16:0), and PBMC lysoPC 
28 
 
(18:0) may indicate that plasma ox-LDL and PBMC Lp-PLA2 activities are major 
determinants of PBMC lysoPC levels. Furthermore, a negative relationship of 
PBMC Lp-PLA2 activities, PBMC lysoPC (16:0), and PBMC lysoPC (18:0) with 
LDL particle size may reflect the apparent binding preference of Lp-PLA2 for small 
dense LDL (42). Similar to a recent report (43), this study also showed positive 
associations among fasting glucose, PBMC Lp-PLA2, and plasma Lp-PLA2 
activities. In a porcine model of diabetes, Shi et al. found the up-regulation of Lp-
PLA2 mRNA expression in PBMC (44).  
In this study, IFG or T2D-related decreases in most plasma lysoPCs were 
observed regardless of increases in plasma Lp-PLA2 activities. This result may 
partly be explained by the previous finding of reduced serum activity of lecithin-
cholesterol acyltransferase (LCAT) in T2D, which transfers a fatty acid from PC to 
cholesterol and also regulates revers cholesterol transport and HDL remodeling 
(45). In the plasma, significant amounts of lysoPCs and most saturated lysoPCs can 
be formed by the action of LCAT (46). Reducing LCAT activity in T2D patients 
was recently suggested to limit the adverse effects of enhanced circulating ox-LDL 
on HDL-cholesterol metabolism (45). This study also showed an increase in 
plasma ox-LDL along with decreases in both HDL-cholesterol and plasma lysoPCs 
containing C16:0, C17:0, C18:2, C18:1, and C18:0. Therefore, IFG or T2D-related 
decreases in most plasma lysoPCs may in part be due to decreased biosynthesis 
resulting from depressed serum LCAT activity rather than increased clearance from 
the circulation by tissues. Whereas LCAT activity was not measured in this study, 
this LCAT-dependent mechanism is a plausible hypothesis.  
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IFG or T2D-related increases in PBMC fatty acid primary amides, oleamide and 
palmitic amide, were observed. Oleamide was the first fatty acid primary amide to 
be identified as a signaling molecule, and it has been shown to participate in 
several signaling pathways (47). This study identified PBMC oleamide (VIP value 
of 11.1721) and PBMC leucine (VIP value of 14.4867) as the most important 
PBMC metabolites for evaluating the difference between healthy patients and 
subjects with IFG or T2D. Recently, Ha et al. (4) found that of the plasma 
metabolites, plasma oleamide was useful for distinguishing between nondiabetic 
and diabetic men (VIP value of 6.952). Our study is in agreement with these 
findings. We found plasma oleamide (VIP value of 13.3814) and plasma lysoPC 
16:0 (VIP value of 16.9894) to be the most important plasma metabolites for 
indicating IFG or T2D. 
A large number of metabolite markers were detected by UPLC-LTQ-Orbitrap 
MS in this study, but most of these metabolites remain unidentified. Large 
databases of endogenous biomolecules have not yet been constructed for use with 
LC-MS-based techniques for metabolomics research (48). Despite these limitations, 
our approach using UPLC-LTQ-Orbitrap MS-based metabolomics and multivariate 
data analysis showed increases in 11 PBMC metabolites in subjects with IFG or 
T2D, including six amino acids (valine, leucine, methionine, phenylalanine, 
tyrosine, tryptophan; all q-values <0.001), L-pyroglutamic acid, palmitic amide, 
oleamide, and two lysoPCs containing C16:0, C18:0. PBMC Lp-PLA2 in 
prediabetic or diabetic individuals. These increases significantly and positively 
correlated with PBMC lysoPCs and circulating inflammatory markers, including 
30 
 
TNF-α, hs-CRP, and Lp-PLA2 activities. However, when we compared the plasma 
of the prediabetic and diabetic patients with controls, we observed significant 
increases in the plasma of only two amino acids, proline and valine; we also 
observed decreases in five lysoPCs containing C16:0, C17:0, C18:2, C18:1, and 
C18:0. In conclusion, this study demonstrates greater differences between patients 
with prediabetes or T2D and healthy controls in the PBMC metabolome than those 
observed in the plasma metabolome. These data indicate that PBMCs may be a 
useful tool to better understand the inflammatory pathophysiology of IFG or 
diabetes. 
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국문요약 
 
당뇨 전단계 및 제 2형 당뇨 환자와 정상인의 
말초혈액단핵구 및 혈장 대사체의 차이 
 
 당뇨 전단계 및 제 2형 당뇨 환자와 정상인의 말초혈액단핵구(PBMC)와 혈장 
대사체의 차이점을 밝히기 위한 연구이다. 당뇨 전단계이거나 제 2형 당뇨로 
새롭게 진단받은 65명의 환자와 성별이 동일한 65명의 비당뇨인이 본 연구에 
참여하였다. 나이와 체질량지수, 혈압, 혈청 지질농도를 보정한 후 당뇨 환자군
에서 PBMC Lp-PLA2 활성도와 C 반응단백질(hs-CRP), 종양괴사인자
(TNF-α)가 대조군보다 더 높았다. 대조군과 비교하여 당뇨 환자군에서 11개
의 PBMC 대사체 (6개의 아미노산, L-pyroglutamic acid, palmitic amide, 
oleamide, 2개의 lysoPCs) 이 더 높았다. 당뇨 환자군에게서 PBMC Lp-
PLA2 은 PBMC lysoPCs 및 염증지표(TNF-α, hs-CRP, Lp-PLA2 활성도)
와 유의적인 양의 상관관계를 보였다. 당뇨 환자군와 대조군의 혈장 대사체를 
비교해보면 2개의 아미노산이 유의적으로 증가하였고, 5개의 lysoPCs만이 유의
적으로 감소하였다. 본 연구를 통하여 당뇨환자와 정상인의 PBMC 대사체가 유
의적으로 다르다는 것을 보였다. 이는 혈장 대사체보다 더 큰 차이이다. 이 결
과로 PBMC가 당뇨의 염증 병태생리를 이해하는데 유용한 지표가 될 수 있을 
것으로 사료된다.  
                                                                                   
핵심되는말: 제2형 당뇨, 당뇨전단계, 말초혈액단핵구 대사체, 혈장 대사체 
염증지표, Lp-PLA2 , TNF-α, lysoPCs, hs-CRP
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